Amgen's Prolia Gains First Regulatory Win, With Market Approval in Europe
Executive Summary
The European Commission has finally granted a marketing authorization for Amgen's bone loss therapy, Prolia (denosumab), five months after CHMP issued a positive opinion
You may also be interested in...
Aranesp Sales Continue To Slide But Amgen Reports A Solid Year
During its fourth-quarter 2009 earnings call, Amgen also reported it has re-filed denosumab for osteoporosis with FDA.
Amgen’s Prolia Bone Drug Is Poised For Clearance In Europe
Two out of three indications ain’t bad: Panel votes for use in post-menopausal osteoporosis and bone loss in prostate cancer.
GSK Denosumab Deal Gives Amgen A Leg Up In Primary Care
Thanks to a new deal with GlaxoSmithKline for the marketing of its cherished bone drug denosumab outside the U.S. in post-menopausal osteoporosis, Amgen gets a much needed, solid launch pad for its first major venture into primary care